600267 海正药业
交易中 11-27 10:28:16
资讯
新帖
简况
海正药业11月18日获主力加仓739万元 环比增加310.56%
市场透视 · 11-18
海正药业11月18日获主力加仓739万元 环比增加310.56%
海正药业:公司产品海博麦布片系公司第一个1类创新药 其成功获批进一步丰富了公司产品线
每日经济新闻 · 11-15
海正药业:公司产品海博麦布片系公司第一个1类创新药 其成功获批进一步丰富了公司产品线
海正药业:目前公司没有开展您所提及的合作事项。关于公司客户和业务合作情况,请以公司公开披露的信息为准
证券之星 · 11-15
海正药业:目前公司没有开展您所提及的合作事项。关于公司客户和业务合作情况,请以公司公开披露的信息为准
海正药业:美罗培南目前尚在首轮集采期,销量不大
格隆汇 · 11-15
海正药业:美罗培南目前尚在首轮集采期,销量不大
海正药业控股子公司获兽药产品批准文号
财中社 · 11-14
海正药业控股子公司获兽药产品批准文号
海正药业(600267.SH)子公司获得兽药产品批准文号批件
智通财经 · 11-14
海正药业(600267.SH)子公司获得兽药产品批准文号批件
海正药业最新公告:子公司获得兽药产品批准文号批件
证券之星 · 11-14
海正药业最新公告:子公司获得兽药产品批准文号批件
海正药业11月14日遭主力抛售554万元 环比增加151.82%
市场透视 · 11-14
海正药业11月14日遭主力抛售554万元 环比增加151.82%
海正药业最新公告:全资子公司获得阿立哌唑片《药品注册证书》
证券之星 · 11-11
海正药业最新公告:全资子公司获得阿立哌唑片《药品注册证书》
海正药业获阿立哌唑片药品注册证书 上半年全球销售额为3.22亿美元
财中社 · 11-11
海正药业获阿立哌唑片药品注册证书 上半年全球销售额为3.22亿美元
海正药业(600267.SH)子公司阿立哌唑片获得药品注册证书 用于治疗精神分裂症
智通财经 · 11-11
海正药业(600267.SH)子公司阿立哌唑片获得药品注册证书 用于治疗精神分裂症
天广实转战北交所:历史沿革疑云密布 “寄生”海正药业或涉国有资产流失?
新浪证券 · 11-08
天广实转战北交所:历史沿革疑云密布 “寄生”海正药业或涉国有资产流失?
海正药业11月06日主力资金流出537万元 连续5日减仓
市场透视 · 11-06
海正药业11月06日主力资金流出537万元 连续5日减仓
海正药业:11月1日接受机构调研,国盛证券、山西证券等多家机构参与
证券之星 · 11-05
海正药业:11月1日接受机构调研,国盛证券、山西证券等多家机构参与
海正药业11月04日主力资金流出1547万元 连续3日减仓
市场透视 · 11-04
海正药业11月04日主力资金流出1547万元 连续3日减仓
深度 | 仿制药利润空间有限、研发项目多折戟,海正药业业绩增长恐难持续
财中社 · 11-04
深度 | 仿制药利润空间有限、研发项目多折戟,海正药业业绩增长恐难持续
海正药业11月01日遭主力抛售2203万元 环比增加549.85%
市场透视 · 11-01
海正药业11月01日遭主力抛售2203万元 环比增加549.85%
海正药业(600267)9月30日股东户数5.63万户,较上期减少3.58%
证券之星 · 10-31
海正药业(600267)9月30日股东户数5.63万户,较上期减少3.58%
海正药业计提1.09亿元资产减值准备 2023年净利润-9317万元
财中社 · 10-31
海正药业计提1.09亿元资产减值准备 2023年净利润-9317万元
海正药业三季度净利润增112.5%,收入微降0.4%
财中社 · 10-31
海正药业三季度净利润增112.5%,收入微降0.4%
加载更多
公司概况
公司名称:
浙江海正药业股份有限公司
所属行业:
医药制造业
上市日期:
2000-07-25
主营业务:
浙江海正药业股份有限公司主营化学原料药和制剂的研发、生产和销售业务,公司的主要产品及服务是医药制剂-自营业务、医药制剂-渠道及创新业务等。公司专注于化学药,生物药,动物药,中药及商业流通等多产业发展,加快布局大健康产业和健康美学等新兴市场,多次入选中国制造业企业500强,中国医药工业百强企业榜单,先后荣获国家技术创新示范企业,全国五一劳动奖状,浙江省政府质量奖等荣誉称号。此外,报告期内公司还获得“2023年度中国化药企业TOP100”,“浙江省知产保护警企合作基地”,“浙江出口名牌”等荣誉。
发行价格:
11.83
{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"海正药业","latestPrice":8.28,"timestamp":1732674496000,"preClose":8.36,"halted":0,"volume":4042900,"delay":0,"floatShares":1198000000,"shares":1208000000,"eps":-0.0168,"marketStatus":"交易中","marketStatusCode":2,"change":-0.08,"latestTime":"11-27 10:28:16","open":8.35,"high":8.38,"low":8.23,"amount":33495300,"amplitude":0.0179,"askPrice":8.29,"askSize":66,"bidPrice":8.28,"bidSize":31,"shortable":0,"etf":0,"ttmEps":-0.0168,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1732678200000},"adr":0,"adjPreClose":8.36,"symbolType":"stock","openAndCloseTimeList":[[1732671000000,1732678200000],[1732683600000,1732690800000]],"highLimit":9.2,"lowLimit":7.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1207873716,"pbRate":1.22,"roa":"--","roe":"6.4%","epsLYR":-0.08,"committee":0.6748,"marketValue":10001000000,"floatMarketCap":9921000000,"peRate":-492.85716,"changeRate":-0.0096,"turnoverRate":0.0034,"status":1},"requestUrl":"/m/hq/s/600267","defaultTab":"news","newsList":[{"id":"2484611639","title":"海正药业11月18日获主力加仓739万元 环比增加310.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484611639","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484611639?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:19","pubTimestamp":1731914344,"startTime":"0","endTime":"0","summary":"11月18日,海正药业股价收平报8.45元,成交金额1.10亿元,换手率1.08%,振幅2.01%,量比0.66。海正药业今日主力资金净流入739万元,上一交易日主力净流入180万元,今日环比增加310.56%。该股近5个交易日下跌3.43%,主力资金累计净流入643万元;近20日主力资金累计净流出7758万元,其中净流出天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152748abcba291&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152748abcba291&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"gpt_icon":0},{"id":"2483320620","title":"海正药业:公司产品海博麦布片系公司第一个1类创新药 其成功获批进一步丰富了公司产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320620","media":"每日经济新闻","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483320620?lang=zh_cn&edition=full","pubTime":"2024-11-15 20:20","pubTimestamp":1731673240,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:您好,公司自有的创新药有哪一些?包含公司孵化已盈利博锐的创新药有哪些?以及在研的创新药有哪些?海正药业(600267.SH)11月15日在投资者互动平台表示,公司产品海博麦布片系公司第一个1类创新药,其成功获批进一步丰富了公司产品线,有助于提升公司产品的市场竞争力;博锐生物现已有7款上市品种(包含创新药、生物类似药)。未来,公司创新药研发将以临床价值和市场价值为导向,聚焦心脑血管、代谢疾病等核心领域,丰富在研管线和拓展新的药物形式。文章来源:每日经济新闻原标题:海正药业:公司产品海博麦布片系公司第一个1类创新药,其成功获批进一步丰富了公司产品线","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115202922abc4a2e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115202922abc4a2e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0239","600267","BK0188","BK0060","159992"],"gpt_icon":0},{"id":"2483347080","title":"海正药业:目前公司没有开展您所提及的合作事项。关于公司客户和业务合作情况,请以公司公开披露的信息为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2483347080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483347080?lang=zh_cn&edition=full","pubTime":"2024-11-15 18:00","pubTimestamp":1731664821,"startTime":"0","endTime":"0","summary":"感谢您的建议,目前公司没有开展您所提及的合作事项。关于公司客户和业务合作情况,请以公司公开披露的信息为准。未来仍将关注股东关切,充分考虑公司经营情况,合理确定现金分红水平。公司各项生产经营正常。美罗培南目前尚在首轮集采期,销量不大,公司会密切关注后续续采机会;多达一产品公司通过多元化经营,恢复情况良好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500031584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600267","BK0060","BK0239"],"gpt_icon":0},{"id":"2483309349","title":"海正药业:美罗培南目前尚在首轮集采期,销量不大","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309349","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483309349?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:47","pubTimestamp":1731660429,"startTime":"0","endTime":"0","summary":"格隆汇11月15日丨海正药业(600267.SH)在互动平台表示,美罗培南目前尚在首轮集采期,销量不大,公司会密切关注后续续采机会;多达一产品公司通过多元化经营,恢复情况良好。公司上下正全力冲刺年初定下的业绩目标,通过公司工业团队持续提高工艺水平,降本增效工作今年初见成效,预计从明年开始,工业产能恢复将会有实质性进展。【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述、观点判断保持中立,不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考,并请自行承担全部责任。邮箱:news_center@staff.hexun.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115165149abc40209&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115165149abc40209&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600267","BK0188","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2483872052","title":"海正药业控股子公司获兽药产品批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2483872052","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483872052?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:19","pubTimestamp":1731586772,"startTime":"0","endTime":"0","summary":"公司控股子公司浙江海正动物保健品有限公司近日收到中华人民共和国农业农村部核准签发的匹莫苯丹咀嚼片和卡洛芬注射液的兽药产品批准文号批件,批准文号有效期为2024年11月8日至2029年11月7日。此次获得的批准文号将丰富公司的兽用药产品线,推动公司在兽药板块的战略布局,提升市场竞争力。2024年前三季度,海正药业实现收入78.75亿元,归母净利润5.15亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114205018abc11f2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114205018abc11f2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0188","BK0239","600267","BK0060"],"gpt_icon":0},{"id":"2483828759","title":"海正药业(600267.SH)子公司获得兽药产品批准文号批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2483828759","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483828759?lang=zh_cn&edition=full","pubTime":"2024-11-14 17:16","pubTimestamp":1731575785,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业 发布公告,近日,公司控股子公司浙江海正动物保健品有限公司收到中华人民共和国农业农村部核准签发的匹莫苯丹咀嚼片、卡洛芬注射液兽药产品批准文号批件。本次海正动保公司获得匹莫苯丹咀嚼片、卡洛芬注射液兽药产品批准文号,将进一步丰富公司兽用药产品线和产品结构,有利于进一步推动公司在兽药板块的战略布局,提升公司市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600267","BK0028","BK0188","BK0239","BK0060"],"gpt_icon":0},{"id":"2483828525","title":"海正药业最新公告:子公司获得兽药产品批准文号批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2483828525","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483828525?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:59","pubTimestamp":1731574786,"startTime":"0","endTime":"0","summary":"海正药业公告,公司控股子公司海正动保公司收到中华人民共和国农业农村部核准签发的匹莫苯丹咀嚼片、卡洛芬注射液兽药产品批准文号批件。匹莫苯丹咀嚼片适用于治疗犬充血性心力衰竭、扩张型心肌病等,卡洛芬注射液适用于缓解犬骨关节炎引起的疼痛和炎症等。此次获得兽药产品批准文号批件,将丰富公司兽用药产品线和产品结构,推动公司在兽药板块的战略布局,提升市场竞争力。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400028330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0060","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2483845217","title":"海正药业11月14日遭主力抛售554万元 环比增加151.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483845217","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483845217?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:18","pubTimestamp":1731568737,"startTime":"0","endTime":"0","summary":"11月14日, 海正药业股价跌2.30%,报收8.49元,成交金额1.23亿元,换手率1.20%,振幅3.11%,量比0.61。海正药业今日主力资金净流出554万元,上一交易日主力净流出220万元,今日环比增加151.82%。该股近5个交易日下跌2.97%,主力资金累计净流出1899万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出8432万元,其中净流出天数为17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114152628a2368294&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114152628a2368294&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600267","BK0060","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2482729270","title":"海正药业最新公告:全资子公司获得阿立哌唑片《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2482729270","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482729270?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:20","pubTimestamp":1731316840,"startTime":"0","endTime":"0","summary":"海正药业公告,公司全资子公司海正药业(杭州)有限公司近日收到国家药监局核准签发的阿立哌唑片《药品注册证书》。该药品主要用于治疗精神分裂症,按新4类获得国家药监局批准上市,视同通过一致性评价。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100022512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","600267","BK0188"],"gpt_icon":0},{"id":"2482270105","title":"海正药业获阿立哌唑片药品注册证书 上半年全球销售额为3.22亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482270105","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482270105?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:16","pubTimestamp":1731316560,"startTime":"0","endTime":"0","summary":"财中社11月11日电海正药业 发布关于获得药品注册证书的公告。公司全资子公司海正药业(杭州)有限公司近日收到国家药品监督管理局核准签发的阿立哌唑片《药品注册证书》。阿立哌唑片主要用于治疗精神分裂症,全球销售额在2023年约为6.86亿美元,其中国内销售额约为4735万美元。2024年上半年,全球销售额为3.22亿美元,国内销售额为2383万美元。2024年前三季度,海正药业实现收入78.75亿元,归母净利润5.15亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111172134abb59f3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111172134abb59f3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"gpt_icon":0},{"id":"2482727247","title":"海正药业(600267.SH)子公司阿立哌唑片获得药品注册证书 用于治疗精神分裂症","url":"https://stock-news.laohu8.com/highlight/detail?id=2482727247","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482727247?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:54","pubTimestamp":1731315290,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,公司全资子公司海正药业(杭州)有限公司于近日收到国家药品监督管理局核准签发的阿立哌唑片《药品注册证书》。阿立哌唑片主要用于治疗精神分裂症,原研厂家为Otsuka。公司阿立哌唑片按新4类获得国家药监局批准上市,视同通过一致性评价。2023年6月29日,国家药监局受理了公司递交的阿立哌唑片的药品注册申请。截至目前,公司在该药品研发项目上已投入约665万元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0028","BK0239","BK0188","600267"],"gpt_icon":0},{"id":"2481231811","title":"天广实转战北交所:历史沿革疑云密布 “寄生”海正药业或涉国有资产流失?","url":"https://stock-news.laohu8.com/highlight/detail?id=2481231811","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481231811?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:32","pubTimestamp":1731058320,"startTime":"0","endTime":"0","summary":" 北交所官网显示,北京天广实生物技术股份有限公司北交所IPO近日获得受理。同年,天广实又向港交所递交申请文件,但最终也无果而终。对历次招股书及相关资料进行梳理后发现,天广实历史延革中存在诸多疑点,或涉及国有资产流失问题。 随后,天广实筹划登陆资本市场。 结合上述的诸多疑点来看,白骅任职海正药业期间留下的巨大“窟窿”,或与天广实有着密切联系。天广实IPO之路屡屡碰壁,是否与国有资产流失有关?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-11-08/doc-incvixhq0637507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0060","BK0239","600267","BK0188"],"gpt_icon":0},{"id":"2481644742","title":"海正药业11月06日主力资金流出537万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2481644742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481644742?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:17","pubTimestamp":1730877433,"startTime":"0","endTime":"0","summary":"11月06日, 海正药业股价跌0.23%,报收8.52元,成交金额1.67亿元,换手率1.63%,振幅1.76%,量比1.29。海正药业今日主力资金净流出537万元,连续5日净流出,上一交易日主力净流出352万元,今日环比增加52.56%。近一年数据显示,该股主力连续5日净流出后,次日下跌概率为60.00%,平均跌幅为1.21%。该股近5个交易日上涨0.83%,主力资金累计净流出4975万元;近20日主力资金累计净流出5776万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106151848a21b92e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106151848a21b92e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0028","600267","BK0239","BK0188"],"gpt_icon":0},{"id":"2481857906","title":"海正药业:11月1日接受机构调研,国盛证券、山西证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2481857906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481857906?lang=zh_cn&edition=full","pubTime":"2024-11-05 19:12","pubTimestamp":1730805127,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年11月5日海正药业发布公告称公司于2024年11月1日接受机构调研,国盛证券、山西证券、汇添富、国新证券、拾芮基金、杭州金蟾蜍投资、君和资本、中国东方资产、申万研究所、国金证券、中信证券、中信建投证券、国泰君安、天风证券、华源证券、西部证券参与。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500031953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002500","BK0188","BK0239","BK0028","BK0276","600267","BK0183","161027","BK0060"],"gpt_icon":0},{"id":"2480324718","title":"海正药业11月04日主力资金流出1547万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2480324718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480324718?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:17","pubTimestamp":1730704640,"startTime":"0","endTime":"0","summary":"11月04日, 海正药业股价涨0.72%,报收8.39元,成交金额9618万元,换手率0.96%,振幅1.20%,量比0.74。海正药业今日主力资金净流出1547万元,连续3日净流出,上一交易日主力净流出2203万元,今日环比减少29.78%。该股近5个交易日下跌3.01%,主力资金累计净流出4076万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出7584万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104151859a213f312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104151859a213f312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"gpt_icon":0},{"id":"2480436603","title":"深度 | 仿制药利润空间有限、研发项目多折戟,海正药业业绩增长恐难持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2480436603","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480436603?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:54","pubTimestamp":1730685249,"startTime":"0","endTime":"0","summary":"2024年前三季度,海正药业计提资产减值损失合计1.87亿元,其中主要是开发支出减值,金额为1.23亿元。2024年前三季度,海正药业实现净利润5.15亿元,这已经是近十年来公司最好的业绩,但考虑到突然出现的1.81亿元的投资收益,公司业绩增长的可持续性恐怕存疑。从盈利能力指标来看,海正药业已经显著跑输行业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104100922a212dac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104100922a212dac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0188","BK0060","600267","BK0028"],"gpt_icon":0},{"id":"2480602707","title":"海正药业11月01日遭主力抛售2203万元 环比增加549.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480602707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480602707?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:17","pubTimestamp":1730445463,"startTime":"0","endTime":"0","summary":"11月01日, 海正药业股价跌1.42%,报收8.33元,成交金额1.28亿元,换手率1.27%,振幅2.72%,量比0.95。海正药业今日主力资金净流出2203万元,上一交易日主力净流出339万元,今日环比增加549.85%。该股近5个交易日下跌2.00%,主力资金累计净流出2812万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出7093万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101152241a20737f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101152241a20737f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0028","600267","BK0239","BK0188"],"gpt_icon":0},{"id":"2479291771","title":"海正药业(600267)9月30日股东户数5.63万户,较上期减少3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479291771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479291771?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:02","pubTimestamp":1730365347,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海正药业披露,截至2024年9月30日公司股东户数为5.63万户,较6月30日减少2093.0户,减幅为3.58%。在化学制药行业个股中,海正药业股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.1万户。从股价来看,2024年6月30日至2024年9月30日,海正药业区间涨幅为22.79%,在此期间股东户数减少2093.0户,减幅为3.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100033052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"gpt_icon":0},{"id":"2479039739","title":"海正药业计提1.09亿元资产减值准备 2023年净利润-9317万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479039739","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479039739?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:16","pubTimestamp":1730344609,"startTime":"0","endTime":"0","summary":"财中社10月31日电海正药业 发布公告称,公司于2024年10月30日召开董事会,决定计提资产减值准备,总额达到1.09亿元。此次减值准备的主要原因是对公司2024年第三季度部分资产进行减值测试,发现存在减值迹象。资产减值损失方面,存货跌价损失为-907万元,开发支出减值为1.23亿元。公司表示,此次计提减值准备将减少2024年第三季度利润总额1.09亿元。2023年,海正药业实现收入103.73亿元,归母净利润-9317万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031114943ab8841b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031114943ab8841b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600267"],"gpt_icon":0},{"id":"2479039732","title":"海正药业三季度净利润增112.5%,收入微降0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479039732","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479039732?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:16","pubTimestamp":1730344608,"startTime":"0","endTime":"0","summary":"截至三季度末,公司总资产162.57亿元,较上年度末下降7.7%;归母净资产为82.53亿元,较上年度末增长1.9%。文章来源:财中社海正药业三季度净利润增112.5%,收入微降0.4%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031113952a1fec134&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031113952a1fec134&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600267"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":-0.0165},{"period":"3month","weight":0.1221},{"period":"6month","weight":0.0787},{"period":"1year","weight":-0.1883},{"period":"ytd","weight":-0.1068}],"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","perCapita":"21275股","boardName":"医药制造业","registeredCapital":"120787万元","compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0121},{"period":"3month","weight":0.1488},{"period":"6month","weight":0.0544},{"period":"1year","weight":0.0752},{"period":"ytd","weight":0.0957}],"survey":" 浙江海正药业股份有限公司主营化学原料药和制剂的研发、生产和销售业务,公司的主要产品及服务是医药制剂-自营业务、医药制剂-渠道及创新业务等。公司专注于化学药,生物药,动物药,中药及商业流通等多产业发展,加快布局大健康产业和健康美学等新兴市场,多次入选中国制造业企业500强,中国医药工业百强企业榜单,先后荣获国家技术创新示范企业,全国五一劳动奖状,浙江省政府质量奖等荣誉称号。此外,报告期内公司还获得“2023年度中国化药企业TOP100”,“浙江省知产保护警企合作基地”,“浙江出口名牌”等荣誉。","serverTime":1732674500581,"listedPrice":11.83,"stockholders":"56319人(较上一季度减少3.58%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海正药业,600267,海正药业股票,海正药业股票老虎,海正药业股票老虎国际,海正药业行情,海正药业股票行情,海正药业股价,海正药业股市,海正药业股票价格,海正药业股票交易,海正药业股票购买,海正药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}